82706-21-6

Basic information

• Product Name: (E)-but-2-en-1-yl ((benzyloxy)carbonyl)glycinate
• Synonyms: (E)-but-2-en-1-yl ((benzyloxy)carbonyl)glycinate
• CAS NO: 82706-21-6
• Molecular Weight: 263.293
• Mol File: 82706-21-6.mol

Chemical Properties

• CAS DataBase Reference: (E)-but-2-en-1-yl ((benzyloxy)carbonyl)glycinate(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-but-2-en-1-yl ((benzyloxy)carbonyl)glycinate(82706-21-6)
• EPA Substance Registry System: (E)-but-2-en-1-yl ((benzyloxy)carbonyl)glycinate(82706-21-6)

Safety Data

• Hazardous Substances Data: 82706-21-6(Hazardous Substances Data)

Upstream product

• 504-61-0 (E)-but-2-enol 
• 1138-80-3 N-(Benzyloxycarbonyl)glycine 

Downstream Products

• 82706-26-1 racemic (2S,3R)-2-(benzyloxycarbonylamino)-3-methylpent-4-enoic acid 
• 82706-72-7 (2S,3S)-2-Benzyloxycarbonylamino-3-methyl-pent-4-enoic acid 

Relevant articles and documents

Evaluation of 3-substituted arginine analogs as selective inhibitors of human nitric oxide synthase isozymes

Nitric oxide (NO), a mediator of various physiological and pathophysiological processes, is synthesized by three isozymes of nitric oxide synthase (NOS). In developing candidate clinical drugs, it is very important not to inhibit endothelial NOS, because

BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE

Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.